

Sara Galimberti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1388998/publications.pdf>

Version: 2024-02-01

346
papers

6,239
citations

87888

38
h-index

114465

63
g-index

351
all docs

351
docs citations

351
times ranked

8805
citing authors

#	ARTICLE	IF	CITATIONS
1	A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. <i>Blood Advances</i> , 2022, 6, 327-338.	5.2	28
2	Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience. <i>Hematological Oncology</i> , 2022, 40, 32-40.	1.7	10
3	COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. <i>British Journal of Haematology</i> , 2022, 196, 559-565.	2.5	20
4	Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 729-739.	1.6	34
5	Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study). <i>Frontiers in Oncology</i> , 2022, 12, 835563.	2.8	6
6	Myeloid neoplasms and autoimmune diseases: markers of association. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 49-55.	0.8	8
7	Diagnostic Workup of Acute Myeloid Leukemia: What Is Really Necessary? An Italian Survey. <i>Frontiers in Oncology</i> , 2022, 12, 828072.	2.8	2
8	Joint Pain and Arthritis as First Clinical Manifestation of Systemic Amyloidosis and Multiple Myeloma: Case Report and Brief Literature Review. <i>Hematology Reports</i> , 2022, 14, 19-23.	0.8	1
9	Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study. <i>Frontiers in Oncology</i> , 2022, 12, 839915.	2.8	10
10	Chronic Myeloid Leukemia and Pregnancy: When Dreams Meet Reality. State of the Art, Management and Outcome of 41 Cases, Nilotinib Placental Transfer. <i>Journal of Clinical Medicine</i> , 2022, 11, 1801.	2.4	10
11	Activation of the zinc-sensing receptor GPR39 promotes T-cell reconstitution after hematopoietic cell transplant in mice. <i>Blood</i> , 2022, 139, 3655-3666.	1.4	10
12	Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool. <i>Diagnostics</i> , 2022, 12, 1305.	2.6	14
13	A Prospective Cross-Sectional Study on the Comparison of Ultrasound Assessment vs. Palpation in Chronic Lymphocytic Leukemia Patients in the Era of Targeted Therapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 3206.	2.4	3
14	BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS. <i>Leukemia</i> , 2021, 35, 2102-2107.	7.2	8
15	Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma. <i>British Journal of Haematology</i> , 2021, 192, 1011-1014.	2.5	2
16	Response assessment to venetoclax in relapsed/refractory chronic lymphocytic leukemia by ultrasonography. <i>Leukemia Research</i> , 2021, 100, 106488.	0.8	3
17	Hematogones in patients with acute myeloid leukaemia: Prognostic value and correlation with minimal residual disease. <i>Leukemia Research Reports</i> , 2021, 15, 100234.	0.4	0
18	Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. <i>European Journal of Haematology</i> , 2021, 106, 493-499.	2.2	5

#	ARTICLE	IF	CITATIONS
19	Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 271-279.	2.5	4
20	Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. <i>American Journal of Hematology</i> , 2021, 96, E168-E171.	4.1	10
21	Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors. <i>Hematological Oncology</i> , 2021, 39, 401-408.	1.7	8
22	Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome. <i>Cancers</i> , 2021, 13, 1311.	3.7	21
23	Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting. <i>Leukemia Research</i> , 2021, 104, 106552.	0.8	4
24	Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice. <i>Pharmacological Research</i> , 2021, 167, 105537.	7.1	12
25	<i>TP53</i> disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. <i>American Journal of Hematology</i> , 2021, 96, E306-E310.	4.1	8
26	Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials. <i>American Journal of Hematology</i> , 2021, 96, E269-E272.	4.1	3
27	Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib. <i>Frontiers in Oncology</i> , 2021, 11, 672287.	2.8	10
28	Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy. <i>Frontiers in Oncology</i> , 2021, 11, 638689.	2.8	0
29	Assessment of droplet digital polymerase chain reaction for measuring <i>BCR-ABL1</i> in chronic myeloid leukaemia in an international interlaboratory study. <i>British Journal of Haematology</i> , 2021, 194, 53-60.	2.5	10
30	COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. <i>British Journal of Haematology</i> , 2021, 195, 371-377.	2.5	56
31	The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms. <i>European Heart Journal</i> , 2021, 42, 4389-4400.	2.2	61
32	Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study. <i>Medicina (Lithuania)</i> , 2021, 57, 900.	2.0	2
33	Real-Life Experience With First-Line Therapy Bortezomib Plus Melphalan and Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma Ineligible for High Dose Chemotherapy With Autologous Stem-Cell Transplantation. <i>Frontiers in Medicine</i> , 2021, 8, 712070.	2.6	4
34	Early Diagnosis of Neutropenic Enterocolitis by Bedside Ultrasound in Hematological Malignancies: A Prospective Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4277.	2.4	6
35	Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study. <i>Acta Oncologica</i> , 2021, 60, 1527-1533.	1.8	2
36	Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma. <i>European Journal of Cancer</i> , 2021, 157, 132-139.	2.8	4

#	ARTICLE	IF	CITATIONS
37	Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy. <i>Cancers</i> , 2021, 13, 291.	3.7	17
38	Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. <i>Annals of Hematology</i> , 2021, 100, 2005-2014.	1.8	14
39	The Slower Antibody Response in Myelofibrosis Patients after Two Doses of mRNA SARS-CoV-2 Vaccine Calls for a Third Dose. <i>Biomedicines</i> , 2021, 9, 1480.	3.2	17
40	From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox. <i>Frontiers in Oncology</i> , 2021, 11, 752192.	2.8	7
41	Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools. <i>Targeted Oncology</i> , 2021, 16, 823-838.	3.6	5
42	Ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a real-life, retrospective, multicenter trial on behalf of the "RTL" (regional Tuscan lymphoma network). <i>American Journal of Blood Research</i> , 2021, 11, 373-383.	0.6	0
43	A Comprehensive and Systematic Analysis of Minimal Residual Disease (MRD) Monitoring in Follicular Lymphoma: Results from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial. <i>Blood</i> , 2021, 138, 41-41.	1.4	0
44	CPX-351 Induction in Secondary Acute Myeloblastic Leukemia: Extended Follow up from the Italian Compassionate Use Program. <i>Blood</i> , 2021, 138, 1262-1262.	1.4	1
45	First Interim Analysis of the Italian Dante Study: De-Escalation before Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Treated with First-Line Nilotinib. <i>Blood</i> , 2021, 138, 1474-1474.	1.4	5
46	Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL. <i>Blood</i> , 2021, 138, 2635-2635.	1.4	1
47	An Observational Study on Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax-Based Regimens Outside Clinical Trials in Italy (GIMEMA CLL1920). <i>Blood</i> , 2021, 138, 3746-3746.	1.4	1
48	Pro-Inflammatory and Pro-Oxidative Changes during Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study). <i>Blood</i> , 2021, 138, 1479-1479.	1.4	1
49	Myeloid neoplasms and autoimmune diseases: markers of association. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	4
50	Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. <i>International Journal of Cardiology</i> , 2020, 301, 163-166.	1.7	21
51	In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent. <i>Leukemia</i> , 2020, 34, 929-931.	7.2	6
52	An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 29-38.	1.8	3
53	CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. <i>Blood Cancer Journal</i> , 2020, 10, 96.	6.2	28
54	Organ Stiffness in the Work-Up of Myelofibrosis and Philadelphia-Negative Chronic Myeloproliferative Neoplasms. <i>Journal of Clinical Medicine</i> , 2020, 9, 2149.	2.4	2

#	ARTICLE	IF	CITATIONS
55	Molecular Testing in CML between Old and New Methods: Are We at a Turning Point?. <i>Journal of Clinical Medicine</i> , 2020, 9, 3865.	2.4	23
56	A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. <i>Journal of Clinical Medicine</i> , 2020, 9, 3692.	2.4	2
57	Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib. <i>Hematological Oncology</i> , 2020, 38, 607-610.	1.7	1
58	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. <i>Lancet Haematology</i> , 2020, 7, e737-e745.	4.6	430
59	Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2. <i>Frontiers in Oncology</i> , 2020, 10, 1428.	2.8	36
60	New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions. <i>Frontiers in Immunology</i> , 2020, 11, 578314.	4.8	55
61	The CoV-2 outbreak: how hematologists could help to fight Covid-19. <i>Pharmacological Research</i> , 2020, 157, 104866.	7.1	36
62	Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia. <i>European Journal of Haematology</i> , 2020, 105, 286-291.	2.2	2
63	Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors. <i>Annals of Hematology</i> , 2020, 99, 1525-1530.	1.8	9
64	Uncommon Presentation of a Common Leukemia (Chronic Lymphocytic Leukemia): Case Report. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 651-652.	0.6	1
65	Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study. <i>Blood Cancer Journal</i> , 2020, 10, 66.	6.2	6
66	Thymic Reconstitution after Damage Is Influenced By Zinc Status. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S304-S305.	2.0	1
67	TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 869-880.	4.1	10
68	Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. <i>Leukemia</i> , 2020, 34, 2260-2261.	7.2	57
69	Digital Droplet PCR is a Specific and Sensitive Tool for Detecting IDH2 Mutations in Acute Myeloid Leukemia Patients. <i>Cancers</i> , 2020, 12, 1738.	3.7	20
70	Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. <i>Blood</i> , 2020, 135, 534-541.	1.4	61
71	Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results. <i>Frontiers in Immunology</i> , 2020, 11, 573156.	4.8	8
72	Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations. <i>Blood</i> , 2020, 136, 43-44.	1.4	2

#	ARTICLE	IF	CITATIONS
73	Proteasome Inhibitors as a Possible Therapy for SARS-CoV-2. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3622.	4.1	45
74	Sorafenib Induced Complete Cytogenetic and Molecular Response in a Chronic Eosinophilic Leukemia Case with t(12;13) Translocation. <i>Clinical Hematology International</i> , 2020, 2, 129.	1.7	1
75	â€œMiroâ€•Study, a FIL multicenter phase II trial combining local radiotherapy and MRD-driven immunotherapy in early-stage follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e20073-e20073.	1.6	1
76	THU0264â€•...MYELOID MALIGNANCIES, SYSTEMIC AUTOIMMUNE DISEASES AND CARDIOVASCULAR RISK: AN UNDER-REPORTED ASSOCIATION?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 359.2-359.	0.9	0
77	Real-life Diagnostic and Therapeutic Approach to CLL: A New Proposal from an Expert Panel in Tuscany Region. <i>Farmeconomia E Percorsi Terapeutici</i> , 2020, 21, .	0.1	0
78	Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2020, 136, 16-17.	1.4	2
79	Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study. <i>Blood</i> , 2020, 136, 47-48.	1.4	0
80	Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study. <i>Blood</i> , 2020, 136, 45-46.	1.4	1
81	Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib. <i>Blood</i> , 2020, 136, 8-9.	1.4	0
82	COVID-19: the new challenge for rheumatologists. First update. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 373-382.	0.8	15
83	Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline. <i>Annals of Hematology</i> , 2019, 98, 2329-2338.	1.8	17
84	Minimal residual disease (MRD) in nonâ€•Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network. <i>Hematological Oncology</i> , 2019, 37, 368-374.	1.7	13
85	The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice. <i>Frontiers in Oncology</i> , 2019, 9, 528.	2.8	27
86	The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2019, 9, 532.	2.8	14
87	â€•Secondary chronic myeloid leukemiaâ€™: comparison between patients previously exposed or not to chemo- and/or radiotherapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 3584-3586.	1.3	5
88	BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2019, 9, 939.	2.8	83
89	231.â€•TRENDS IN LONG-TERM OUTCOMES IN EGPA: A SINGLE CENTER EXPERIENCE. <i>Rheumatology</i> , 2019, 58, .	1.9	0
90	Interference of Monoclonal Gammopathy with Fibrinogen Assay Producing Spurious Dysfibrinogenemia. <i>TH Open</i> , 2019, 03, e64-e66.	1.4	8

#	ARTICLE	IF	CITATIONS
91	Monitoring Chronic Myeloid Leukemia: How Molecular Tools May Drive Therapeutic Approaches. <i>Frontiers in Oncology</i> , 2019, 9, 833.	2.8	17
92	RESPONSE ORIENTED MAINTENANCE THERAPY IN ADVANCED FOLLICULAR LYMPHOMA. RESULTS OF THE INTERIM ANALYSIS OF THE FOLL12 TRIAL CONDUCTED BY THE FONDAZIONE ITALIANA LINFOMI.. <i>Hematological Oncology</i> , 2019, 37, 153-154.	1.7	19
93	Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice. <i>Annals of Hematology</i> , 2019, 98, 1885-1890.	1.8	10
94	Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention. <i>International Journal of Cardiology</i> , 2019, 288, 124-127.	1.7	19
95	The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients. <i>Cancer Cell International</i> , 2019, 19, 83.	4.1	3
96	Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. <i>Hematological Oncology</i> , 2019, 37, 296-302.	1.7	53
97	Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. <i>Haematologica</i> , 2019, 104, 1589-1596.	3.5	58
98	Chronic Myeloid Leukemia Patient's Voice About the Experience of Treatment-Free Remission Failure: Results From the Italian Sub-Study of ENESTPath Exploring the Emotional Experience of Patients During Different Phases of a Clinical Trial. <i>Frontiers in Psychology</i> , 2019, 10, 329.	2.1	6
99	USEFULNESS OF BIOMARKERS OF EOSINOPHIL ACTIVATION IN MONITORING EGPA DISEASE ACTIVITY. <i>Rheumatology</i> , 2019, 58, .	1.9	0
100	Flow Cytometry Assessment of CD26 + Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 294-299.	1.5	28
101	Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. <i>Blood Advances</i> , 2019, 3, 4280-4290.	5.2	66
102	Different types of amyloid concomitantly present in the same patients. <i>Hematology Reports</i> , 2019, 11, 7996.	0.8	3
103	Precision Medicine in Lymphoma by Innovative Instrumental Platforms. <i>Frontiers in Oncology</i> , 2019, 9, 1417.	2.8	12
104	Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. <i>Journal of Hematology and Oncology</i> , 2019, 12, 131.	17.0	45
105	The Onset of Monoclonal and Oligoclonal Gammopathies Is a Good Prognostic Factor after Allogeneic Stem Cell Transplantation. <i>Acta Haematologica</i> , 2019, 141, 7-11.	1.4	0
106	Prospective Monitoring of Peripheral Blood CD26+ Leukemia Stem Cells in Chronic Myeloid Leukemia Patients from Time of TKI Discontinuation. <i>Blood</i> , 2019, 134, 2919-2919.	1.4	2
107	EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy. <i>Blood</i> , 2019, 134, 124-124.	1.4	6
108	Preliminary Results of CML1214, a Survey on Ponatinib Compassionate Use in Italy By the Gimema CML Working Party. <i>Blood</i> , 2019, 134, 2931-2931.	1.4	2

#	ARTICLE	IF	CITATIONS
109	Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making. <i>Blood</i> , 2019, 134, 661-661.	1.4	5
110	Bosutinib in the Real-Life Treatment of Chronic Phase Chronic Myeloid Leukemia (CML) Patients Aged > 65 Years Resistant/Intolerant to Frontline Tyrosine-Kynase Inhibitors. <i>Blood</i> , 2019, 134, 1649-1649.	1.4	7
111	Zinc Treatment Stimulates Thymic Regeneration after Bone Marrow Transplant. <i>Blood</i> , 2019, 134, 4422-4422.	1.4	3
112	Clinical Relevance of Individual Response to Iron Chelation Therapy (ICT) in Patients with Myelodysplastic Syndromes (MDS) and Transfusion Requirement. <i>Blood</i> , 2019, 134, 3010-3010.	1.4	0
113	A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. <i>Blood</i> , 2019, 134, 4153-4153.	1.4	0
114	Aurora Kinase α /MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way. <i>Blood</i> , 2019, 134, 4142-4142.	1.4	0
115	COO, MYC / BCL2 Status and R-IPI Define a Group of Poor Prognosis DLBCL Patients in a Real-World Clinical Setting. <i>Blood</i> , 2019, 134, 1617-1617.	1.4	0
116	The Impact of Different Mobilization Strategies in the Setting of Multiple Myeloma. <i>Blood</i> , 2019, 134, 3254-3254.	1.4	0
117	Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis. <i>American Journal of Hematology</i> , 2018, 93, E159-E161.	4.1	26
118	Plasma Cell Disorders and Dialysis-Dependent Renal Failure: Safety and Efficacy of Autologous Stem Cell Transplantation. <i>Acta Haematologica</i> , 2018, 139, 101-103.	1.4	1
119	Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment. <i>Stem Cells Translational Medicine</i> , 2018, 7, 305-314.	3.3	65
120	High-dose zinc oral supplementation after stem cell transplantation causes an increase of TRECs and CD4+ na ⁺ ve lymphocytes and prevents TTV reactivation. <i>Leukemia Research</i> , 2018, 70, 20-24.	0.8	36
121	Highly sensitive MYD88 ^{L265P} mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia. <i>Haematologica</i> , 2018, 103, 1029-1037.	3.5	61
122	Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome. <i>British Journal of Haematology</i> , 2018, 181, 267-270.	2.5	8
123	Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. <i>Annals of Hematology</i> , 2018, 97, 95-100.	1.8	32
124	MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine. <i>Pharmacogenomics Journal</i> , 2018, 18, 444-449.	2.0	2
125	The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2018, 8, 555.	2.8	18
126	Torquetenovirus (TTV) load is associated with mortality in Italian elderly subjects. <i>Experimental Gerontology</i> , 2018, 112, 103-111.	2.8	25

#	ARTICLE	IF	CITATIONS
127	Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission. <i>Frontiers in Oncology</i> , 2018, 8, 194.	2.8	84
128	Ficollâ€Chypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis. <i>International Journal of Laboratory Hematology</i> , 2018, 40, 201-208.	1.3	8
129	Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Ponatinib in the Real-Life Practice: Prophylaxis and Identification of Risk Factors. <i>Blood</i> , 2018, 132, 3006-3006.	1.4	1
130	Zinc Supplementation Improves T Cell Reconstitution after Allogeneic HSCT By Stimulating Endogenous Pathways of Thymic Regeneration. <i>Blood</i> , 2018, 132, 3321-3321.	1.4	2
131	Next Generation Sequencing-Based BCR-ABL1 Kinase Domain Mutation Screening in De Novo and Tyrosine Kinase Inhibitor-Resistant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of a Prospective Study. <i>Blood</i> , 2018, 132, 4078-4078.	1.4	1
132	Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing. <i>Blood</i> , 2018, 132, 789-789.	1.4	3
133	Gimema Registry of Conception/Pregnancy in Adult Italian Patients Diagnosed with Chronic Myeloid Leukemia (CML): Report on 166 Outcomes. <i>Blood</i> , 2018, 132, 43-43.	1.4	10
134	Frontline Treatment with Dasatinib in Very Elderly Patients (> 75 Years) with Chronic Myeloid Leukemia: Is It Feasible?. <i>Blood</i> , 2018, 132, 5438-5438.	1.4	0
135	Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Induces Genetic Instability and Can be Therapeutically Targeted. <i>Blood</i> , 2018, 132, 1726-1726.	1.4	0
136	Risk of Histological Transformation in Patients with Primary Refractory Follicular Lymphoma. <i>Blood</i> , 2018, 132, 4145-4145.	1.4	0
137	"Secondary Chronic Myeloid Leukemia": Comparison between Patients Previously Exposed or Not to Chemo and/or Radiotherapy. <i>Blood</i> , 2018, 132, 5437-5437.	1.4	2
138	Real Life Evaluation of Efficacy and Safety of Bosutinib Therapy in Chronic Myeloid Leukemia Patients. <i>Blood</i> , 2018, 132, 3021-3021.	1.4	0
139	Recovering from chronic myeloid leukemia: the patientsâ€™ perspective seen through the lens of narrative medicine. <i>Quality of Life Research</i> , 2017, 26, 2739-2754.	3.1	16
140	Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 767-773.	2.3	12
141	THU0308â€...Extensive analysis of T cell receptor gamma (TCRC) gene rearrangements reveals a similar repertoire in eosinophilic granulomatosis with polyangiitis (EGPA) and in hypereosinophilic syndrome (HES). , 2017, , .		0
142	HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia. <i>Leukemia Research</i> , 2017, 61, 1-5.	0.8	12
143	Establishing a National Network of Laboratories Using Next Generation Amplicon Deep Sequencing for BCR-ABL1 Kinase Domain Mutation Screening in Philadelphia Chromosome-Positive Leukemias: the â€NEXT-IN-CML' Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S310-S311.	0.4	0
144	Pharmacogenetics and Personalized Medicine. , 2017, , 149-168.		1

#	ARTICLE	IF	CITATIONS
145	How to treat splenic marginal zone lymphoma (SMZL) in patients unfit for surgery or more aggressive therapies: experience in 30 cases. <i>Journal of Chemotherapy</i> , 2017, 29, 126-129.	1.5	12
146	The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study. <i>Frontiers in Pharmacology</i> , 2017, 8, 413.	3.5	4
147	ED-B fibronectin expression is a marker of epithelial-mesenchymal transition in translational oncology. <i>Oncotarget</i> , 2017, 8, 4914-4921.	1.8	32
148	PRDI-BF1 and PRDI-BF1 ² isoform expressions correlate with disease status in multiple myeloma patients. <i>Hematology Reports</i> , 2017, 9, 7201.	0.8	2
149	Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup. <i>Oncotarget</i> , 2017, 8, 79188-79200.	1.8	5
150	The <i>hOCT1</i> and <i>ABCB1</i> polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 88021-88033.	1.8	14
151	GTF2I Mutations Are Common in Thymic Epithelial Tumors But Not in Hematological Malignancies. , 2017, 37, 5459-5462.		9
152	Radionuclide Therapy of Leukemias and Multiple Myeloma. , 2017, , 1157-1195.		0
153	Diagnostic Applications of Nuclear Medicine: Multiple Myeloma. , 2017, , 395-433.		1
154	Diagnostic Applications of Nuclear Medicine: Leukemias. , 2017, , 435-465.		0
155	The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia. <i>Frontiers in Pharmacology</i> , 2016, 7, 363.	3.5	26
156	Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients. <i>Journal of Hematology and Oncology</i> , 2016, 9, 63.	17.0	18
157	Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2016, 34, 1175-1181.	1.6	94
158	Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. <i>Neoplasia</i> , 2016, 18, 536-540.	5.3	24
159	Panobinostat for the treatment of acute myelogenous leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1117-1131.	4.1	23
160	ATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overview. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1419-1432.	3.3	46
161	Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLLO5 trial of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2016, 101, e66-e68.	3.5	36
162	Microwave ablation of hepatic tumors with a third generation system: loco-regional efficacy in a prospective cohort study with intermediate term follow-up. <i>Zeitschrift Fur Gastroenterologie</i> , 2016, 54, 541-547.	0.5	12

#	ARTICLE	IF	CITATIONS
163	Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis. <i>Supportive Care in Cancer</i> , 2016, 24, 4487-4493.	2.2	9
164	Comparison of different DNA extraction methods from peripheral blood cells: advice from the Fondazione Italiana Linfomi Minimal Residual Disease Network. <i>Leukemia and Lymphoma</i> , 2016, 57, 400-410.	1.3	4
165	The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia. <i>Annals of Hematology</i> , 2016, 95, 211-219.	1.8	18
166	Phase II Study of the Combination of Interleukin-2 with Zoledronic Acid As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. <i>Blood</i> , 2016, 128, 5697-5697.	1.4	2
167	Peripheral Blood Flow-Cytometry Chronic Myeloid Leukemia Stem Cells Detection and Quantification during Tyrosine Kinase Inhibitors Therapy. <i>Blood</i> , 2016, 128, 942-942.	1.4	2
168	Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients. <i>Oncotarget</i> , 2016, 7, 72311-72321.	1.8	26
169	Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. <i>Oncotarget</i> , 2016, 7, 80083-80090.	1.8	24
170	The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy. <i>Blood</i> , 2016, 128, 3097-3097.	1.4	0
171	Zinc Oral Supplementation Induces a Significant Rise of TRECs and T CD4+ Naïve and Prevents the Increase of Ttv Viral Load after Stem Cell Transplantation: The Zenith Study. <i>Blood</i> , 2016, 128, 1230-1230.	1.4	0
172	Young CML Patients Treated Frontline with Imatinib or Second Generation TKIs: Clinical Characteristics and Outcome. <i>Blood</i> , 2016, 128, 3078-3078.	1.4	0
173	The hOCT1 and ABCB1 Polymorphisms Don't Condition the Efficacy and Toxicity of Nilotinib As First-Line Treatment: An Italian Multicentric Experience. <i>Blood</i> , 2016, 128, 3951-3951.	1.4	0
174	Reduced circulating B-lymphocytes and altered B-cell compartments in patients suffering from chronic myeloid leukaemia undergoing therapy with Imatinib. <i>Hematological Oncology</i> , 2015, 33, 250-252.	1.7	3
175	Real-time PCR and Droplet Digital PCR: two techniques for detection of the <i>JAK2</i> V617F mutation in Philadelphia-negative chronic myeloproliferative neoplasms. <i>International Journal of Laboratory Hematology</i> , 2015, 37, 766-773.	1.3	30
176	Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2015, 16, 22811-22829.	4.1	33
177	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015, 26, 185-192.	1.2	72
178	Increased values of the circulating PDGF β sustains the 'withdrawal syndrome' after tyrosine kinase inhibitor discontinuation in patients affected by chronic myeloid leukemia. <i>Blood Cells, Molecules, and Diseases</i> , 2015, 55, 211-212.	1.4	6
179	The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study. <i>Haematologica</i> , 2015, 100, 517-524.	3.5	6
180	Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients. <i>Experimental Hematology</i> , 2015, 43, 1015-1018.e1.	0.4	51

#	ARTICLE	IF	CITATIONS
181	Polycomb genes are associated with response to imatinib in chronic myeloid leukemia. <i>Epigenomics</i> , 2015, 7, 757-765.	2.1	22
182	Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myeloid Leukemia: Comparison with FISH and PCR Techniques. <i>PLoS ONE</i> , 2015, 10, e0130360.	2.5	4
183	Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study. <i>Turkish Journal of Haematology</i> , 2015, 32, 206-212.	0.5	4
184	The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. <i>Pharmacogenomics Journal</i> , 2014, 14, 328-335.	2.0	45
185	Safety and efficacy of ⁹⁰<sc>Y</sc>triumâ€<sc>I</sc>britumomabâ€<sc>T</sc>iuxetan for untreated follicular lymphoma patients. An <sc>I</sc>talian cooperative study. <i>British Journal of Haematology</i> , 2014, 164, 710-716.	2.5	31
186	Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain reaction performance. <i>Hematological Oncology</i> , 2014, 32, 133-138.	1.7	10
187	No reactivation of JCV in bone marrow of follicular lymphoma patients treated front-line with rituximab plus 90y-ibritumomab tiuxetan. <i>Infection</i> , 2014, 42, 1065-1066.	4.7	0
188	Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial. <i>Clinical Cancer Research</i> , 2014, 20, 6398-6405.	7.0	94
189	Imaging studies in extramedullary hematopoiesis of the spleen. <i>Annals of Hematology</i> , 2014, 93, 347-349.	1.8	2
190	Sorafenib As Monotherapy or in Association With Cytarabine and Clofarabine for the Treatment of Relapsed/Refractory FLT3 ITD-Positive Advanced Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e13-e17.	0.4	3
191	CD69, a New Potential Clinical Marker in Multiple Myeloma. <i>Blood</i> , 2014, 124, 2027-2027.	1.4	2
192	Non Pegylated Liposomal Doxorubicin in Combination with Dexamethasone and Lenalidomide (RMD) Is Active in Advanced MM. <i>Blood</i> , 2014, 124, 5742-5742.	1.4	0
193	Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study. <i>Annals of Hematology</i> , 2013, 92, 25-32.	1.8	23
194	Prospective qualitative and quantitative non-invasive evaluation of intestinal acute GVHD by contrast-enhanced ultrasound sonography. <i>Bone Marrow Transplantation</i> , 2013, 48, 1421-1428.	2.4	21
195	The value of repeat biopsy in the management of lupus nephritis: an international multicentre study in a large cohort of patients. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 3014-3023.	0.7	55
196	Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. <i>Leukemia and Lymphoma</i> , 2013, 54, 2458-2465.	1.3	29
197	R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLL05 Trial Conducted by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2013, 31, 1506-1513.	1.6	223
198	The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. <i>Annals of Oncology</i> , 2013, 24, 454-462.	1.2	232

#	ARTICLE	IF	CITATIONS
199	Significant efficacy of 2-chlorodeoxyadenosine± rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up. <i>Annals of Oncology</i> , 2013, 24, 2434-2438.	1.2	17
200	Bortezomib with Thalidomide plus Dexamethasone Compared with Thalidomide plus Doxorubicin and Dexamethasone as Induction Therapy in Previously Untreated Multiple Myeloma Patients. <i>Acta Haematologica</i> , 2013, 129, 35-39.	1.4	7
201	Foods, nutrients and the risk of oral and pharyngeal cancer. <i>British Journal of Cancer</i> , 2013, 109, 2904-2910.	6.4	95
202	Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. <i>Blood Cancer Journal</i> , 2013, 3, e162-e162.	6.2	56
203	Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. <i>Blood</i> , 2013, 122, 3759-3766.	1.4	82
204	THU0205â€¦The temporal appearance of symptoms and signs in churg strauss syndrome: From the prodromal phase to damage. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 224.3-224.	0.9	0
205	Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status?. <i>Blood</i> , 2013, 122, 1482-1482.	1.4	6
206	VDTPACEÂAs Salvage Therapy For Heavily Pretreated MM Patients. <i>Blood</i> , 2013, 122, 5377-5377.	1.4	11
207	Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study. <i>Journal of Hematology and Oncology</i> , 2012, 5, 53.	17.0	9
208	Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. <i>British Journal of Haematology</i> , 2012, 156, 346-353.	2.5	122
209	Could age modify the effect of genetic variants in IL6 and TNF-Î± genes in multiple myeloma?. <i>Leukemia Research</i> , 2012, 36, 594-597.	0.8	13
210	Molecular Remission After VTD or TAD As Induction for Multiple Myeloma: Results with Two Different Methods of Analysis.. <i>Blood</i> , 2012, 120, 2929-2929.	1.4	0
211	Outcome of patients with mantle cell lymphoma is not influenced by vascular endothelial growth factor polymorphisms. <i>Leukemia and Lymphoma</i> , 2011, 52, 142-144.	1.3	2
212	Impaired function of gamma-delta lymphocytes in melanoma patients. <i>European Journal of Clinical Investigation</i> , 2011, 41, 1186-1194.	3.4	20
213	Discordant lymphoma consisting of splenic mantle cell lymphoma and marginal zone lymphoma involving the bone marrow and peripheral blood: a case report. <i>Journal of Medical Case Reports</i> , 2011, 5, 476.	0.8	4
214	Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients. <i>Annals of Hematology</i> , 2011, 90, 1115-1116.	1.8	3
215	Correspondence between salivary proteomic pattern and clinical course in primary SjÃ¶rgren syndrome and non-Hodgkin's lymphoma: a case report. <i>Journal of Translational Medicine</i> , 2011, 9, 188.	4.4	22
216	Highâ€dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: A retrospective investigation on 133 patients treated in a single institution. <i>American Journal of Hematology</i> , 2011, 86, 762-767.	4.1	6

#	ARTICLE	IF	CITATIONS
217	Autologous purified peripheral blood SCT in childhood low-risk relapsed ALL. Bone Marrow Transplantation, 2011, 46, 217-226.	2.4	4
218	Safety and Efficacy of 90Y Ibritumomab Tiuxetan (Zevalin®) for Untreated Follicular Non-Hodgkin's Lymphoma (FL) Patients, An Italian Cooperative Study. Blood, 2011, 118, 100-100.	1.4	0
219	Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. Cancer Genetics and Cytogenetics, 2010, 199, 110-120.	1.0	21
220	Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. European Journal of Haematology, 2010, 84, 223-228.	2.2	77
221	Changes in <i>RPS14</i> expression levels during lenalidomide treatment in Low and Intermediate risk myelodysplastic syndromes with chromosome 5q deletion. European Journal of Haematology, 2010, 85, 231-235.	2.2	25
222	2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. Leukemia Research, 2010, 34, 184-189.	0.8	28
223	Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib. Leukemia Research, 2010, 34, 1336-1339.	0.8	17
224	<i>WT1</i> expression levels at diagnosis could predict long term time to progression in adult patients affected by acute myeloid leukaemia and myelodysplastic syndromes. British Journal of Haematology, 2010, 149, 451-454.	2.5	23
225	correspondence: CD23 expression in plasma cell leukaemia. British Journal of Haematology, 2010, 150, 724-725.	2.5	4
226	Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma. Cancer Management and Research, 2010, 2, 181.	1.9	10
227	Vascular Endothelial Growth Factor Polymorphisms in Mantle Cell Lymphoma. Acta Haematologica, 2010, 123, 91-95.	1.4	17
228	Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). Annals of Oncology, 2010, 21, 851-854.	1.2	32
229	Age-Dependent Influence of TNF- \pm Polymorphism on Progression Free Survival of ASCT In Multiple Myeloma Patients. Blood, 2010, 116, 1829-1829.	1.4	0
230	Safety and Efficacy of Pegylated Liposomal Doxorubicin In Combination with Dexamethasone and Bortezomib (VMD) or Lenalidomide (RMD) In Multiple Myeloma Refractory/Relapsed Patients. Blood, 2010, 116, 5033-5033.	1.4	0
231	ITF2357 interferes with apoptosis and inflammatory pathways in the HL-60 model: a gene expression study. Anticancer Research, 2010, 30, 4525-35.	1.1	6
232	Bortezomib and Liposomal Doxorubicin Are Highly Effective in Obtaining the Best Possible Response before Autologous Transplant for Multiple Myeloma. Acta Haematologica, 2009, 122, 39-41.	1.4	2
233	Fatal ongoing human cytomegalovirus reactivation during high-dose melphalan and autologous stem cell transplantation. Journal of Medical Virology, 2009, 81, 857-860.	5.0	6
234	P112 Gene expression patterns in MDS with del5q before and during lenalidomide treatment. Leukemia Research, 2009, 33, S124.	0.8	0

#	ARTICLE	IF	CITATIONS
235	Platelet-derived growth factor beta receptor (<i>PDGFRB</i>) gene is rearranged in a significant percentage of myelodysplastic syndromes with normal karyotype. <i>British Journal of Haematology</i> , 2009, 147, 763-766.	2.5	7
236	Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-δ T cells. <i>European Journal of Clinical Investigation</i> , 2009, 39, 813-818.	3.4	23
237	Vorinostat interferes with Wnt and NF-κB pathways in the M-07e cell line. <i>Leukemia</i> , 2009, 23, 1935-1938.	7.2	4
238	Enhancement of hematopoietic stem cell engraftment by inhibition of CXCL12 proteolysis with sitagliptin, an oral dipeptidyl-peptidase IV inhibitor: A report in a case of delayed graft failure. <i>Leukemia Research</i> , 2009, 33, 178-181.	0.8	7
239	Hyperbaric oxygen therapy in BKV-associated hemorrhagic cystitis refractory to intravenous and intravesical cidofovir: Case report and review of literature. <i>Leukemia Research</i> , 2009, 33, 556-560.	0.8	24
240	Hypercytokinemia-induced metabolic encephalopathy in a multiple myeloma patient on hemodialysis undergoing autologous stem cell transplantation: Clinical response after plasma exchange. <i>Transplant Immunology</i> , 2009, 21, 240-243.	1.2	4
241	Contrast-enhanced ultrasonography in nodular splenomegaly associated with type B Niemann-Pick disease: an atypical hemangioma enhancement pattern. <i>Journal of Ultrasound</i> , 2009, 12, 85-92.	1.3	9
242	MDR1 C3435T Polymorphism Indicates a Different Outcome in Advanced Multiple Myeloma. <i>Acta Haematologica</i> , 2009, 122, 42-45.	1.4	10
243	Aggressive Non Hodgkin lymphoma' patients Treated by High Dose Chemotherapy and Immunotherapy Has a Lower Relapse Rate: Results of a Computer Science Analysis.. <i>Blood</i> , 2009, 114, 4772-4772.	1.4	0
244	Optimizing Follow up Schedule for Non Hodgkin Lymphoma' Patients by Multi-Objective Analysis.. <i>Blood</i> , 2009, 114, 3945-3945.	1.4	0
245	The Role of Imaging in Relapse Detection During Follow up: a Fifteen-Year Single Center Experience.. <i>Blood</i> , 2009, 114, 5007-5007.	1.4	4
246	Association in Outcome of Advanced Multiple Myeloma with Polymorphisms of Inflammatory-Related Genes IL-1A, IL-1B, IL1RN, TNF-a and TNFRSF1B.. <i>Blood</i> , 2009, 114, 1723-1723.	1.4	0
247	Long-term propylthiouracil use and acute myeloid leukemia: A case report and review of the literature. <i>Annals of Hematology</i> , 2008, 87, 233-235.	1.8	5
248	Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature. <i>Annals of Hematology</i> , 2008, 87, 405-412.	1.8	76
249	False positive PET scanning caused by inactivated influenza virus vaccination during complete remission from anaplastic T-cell lymphoma. <i>Annals of Hematology</i> , 2008, 87, 343-344.	1.8	22
250	MDR1 modulates apoptosis in CD34+ leukemic cells. <i>Annals of Hematology</i> , 2008, 87, 1017-1018.	1.8	4
251	Human autologous plasma-derived clot as a biological scaffold for mesenchymal stem cells in treatment of orthopedic healing. <i>Journal of Orthopaedic Research</i> , 2008, 26, 176-183.	2.3	34
252	Gelatin/PLLA Sponge-Like Scaffolds Allow Proliferation and Osteogenic Differentiation of Human Mesenchymal Stromal Cells. <i>Macromolecular Bioscience</i> , 2008, 8, 819-826.	4.1	24

#	ARTICLE	IF	CITATIONS
253	Acute myeloid leukaemia after treatment with ⁹⁰ Y-ibritumomab tiuxetan for follicular lymphoma. <i>Hematological Oncology</i> , 2008, 26, 179-181.	1.7	6
254	Concomitant translocation t(14;22)(q32;q11) in a case of chronic myeloid leukemia. <i>Leukemia Research</i> , 2008, 32, 188-190.	0.8	1
255	Complex translocation t(6;9;22)(p21.1;q34;q11) at diagnosis is a therapy resistance index in chronic myeloid leukaemia. <i>Leukemia Research</i> , 2008, 32, 190-191.	0.8	6
256	Complex translocation t(3;9;22)(q21;q34;q11) at diagnosis is a negative prognostic index in chronic myeloid leukemia. <i>Leukemia Research</i> , 2008, 32, 192-194.	0.8	4
257	Reduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemia. <i>Leukemia Research</i> , 2008, 32, 191-192.	0.8	9
258	Transitory marrow aplasia during Imatinib therapy in a patient with chronic myeloid leukemia. <i>Leukemia Research</i> , 2008, 32, 194-195.	0.8	5
259	Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms. <i>Leukemia Research</i> , 2008, 32, 49-53.	0.8	8
260	PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells. <i>Leukemia Research</i> , 2008, 32, 103-112.	0.8	14
261	MDR1 pump: More than a drug transporter. <i>Leukemia Research</i> , 2008, 32, 359-360.	0.8	2
262	Lack of association of NQO1 and GSTP1 polymorphisms with multiple myeloma risk. <i>Leukemia Research</i> , 2008, 32, 988-990.	0.8	15
263	Bortezomib is able to reduce angiogenesis in half of patients affected by idiopathic myelofibrosis: An ex vivo study. <i>Leukemia Research</i> , 2008, 32, 1324-1325.	0.8	3
264	JAK-2V617F mutation in RARS-t: A target for Imatinib therapy?. <i>Leukemia Research</i> , 2008, 32, 1636-1637.	0.8	5
265	Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines. <i>Leukemia</i> , 2008, 22, 628-631.	7.2	11
266	Good manufacturing practice- [®] grade fibrin gel is useful as a scaffold for human mesenchymal stromal cells and supports in vitro osteogenic differentiation. <i>Transfusion</i> , 2008, 48, 2246-2251.	1.6	21
267	Preemptive valganciclovir for cytomegalovirus infection in hematological patients. <i>Transplant Infectious Disease</i> , 2008, 10, 375-376.	1.7	1
268	Rituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow-up. <i>British Journal of Haematology</i> , 2008, 143, 296-298.	2.5	31
269	Unusual association of endometrial cancer and multiple myeloma. <i>Gynecologic Oncology</i> , 2008, 110, 265-266.	1.4	7
270	Other mechanisms to explain the role of reduced folate carrier in cancer. <i>European Journal of Haematology</i> , 2008, 80, 365-365.	2.2	0

#	ARTICLE	IF	CITATIONS
271	Ultrasound findings guided a successful hemicolectomy in a leukemic patient with neutropenic enterocolitis. <i>Journal of Ultrasound</i> , 2008, 11, 97-101.	1.3	3
272	Conditioning response to granulocyte colony-stimulating factor via the dipeptidyl peptidase IV-adenosine deaminase complex. <i>Journal of Leukocyte Biology</i> , 2008, 84, 331-337.	3.3	6
273	Phenobarbital-Associated Bone Marrow Aplasia: A Case Report and Review of the Literature. <i>Acta Haematologica</i> , 2008, 119, 18-21.	1.4	9
274	MDR1 diplotypes as prognostic markers in multiple myeloma. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 383-389.	1.5	30
275	Bortezomib (VEL) Based Regimens in Multiple Myeloma (MM) Patients with Renal Impairment (RI): A Preliminary Retrospective Italian Multicenter Study. <i>Blood</i> , 2008, 112, 3681-3681.	1.4	1
276	TNF- α Polymorphism Modulates the Outcome of Multiple Myeloma Patients Treated with Bortezomib. <i>Blood</i> , 2008, 112, 216-216.	1.4	1
277	Evaluation of the MDR1, ABCG2, Topoisomerase II α and GST π gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen. <i>Leukemia and Lymphoma</i> , 2007, 48, 1502-1509.	1.3	15
278	Effects of <i>Aspergillus fumigatus</i> gliotoxin and methylprednisolone on human neutrophils: implications for the pathogenesis of invasive aspergillosis. <i>Journal of Leukocyte Biology</i> , 2007, 82, 839-848.	3.3	61
279	The Efficacy of Rituximab plus Hyper-CVAD Regimen in Mantle Cell Lymphoma Is Independent of FC γ RIIIa and FC γ RIIIa Polymorphisms. <i>Journal of Chemotherapy</i> , 2007, 19, 315-321.	1.5	17
280	Two Cases of Plasma Cell Leukemia with Atypical Immunophenotype. <i>Acta Haematologica</i> , 2007, 118, 27-29.	1.4	7
281	Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases. <i>Haematologica</i> , 2007, 92, e96-e97.	3.5	5
282	Suspension of Bone Marrow-Derived Undifferentiated Mesenchymal Stromal Cells for Repair of Superficial Digital Flexor Tendon in Race Horses. <i>Tissue Engineering</i> , 2007, 13, 2949-2955.	4.6	179
283	Characterization of Ph-negative abnormal clones emerging during imatinib therapy. <i>Cancer</i> , 2007, 109, 2466-2472.	4.1	29
284	Bortezomib inhibits T-cell function versus infective antigenic stimuli in a dose-dependent manner in vitro. <i>Leukemia Research</i> , 2007, 31, 1026-1027.	0.8	5
285	Match unrelated bone marrow transplantation in a case of high risk myelodysplastic syndrome treated with azacitidine and concomitant 1 α -25-dihydroxyvitamin D ₃ , as differentiating agent. <i>Leukemia Research</i> , 2007, 31, 1321-1323.	0.8	1
286	Folate levels and methylation of CDKI proteins. <i>Leukemia Research</i> , 2007, 31, 569-570.	0.8	4
287	PEG-Filgrastim activity on granulocyte functions. <i>Leukemia Research</i> , 2007, 31, 1453-1455.	0.8	9
288	A therapy resistant myelodysplastic syndrome characterized by the presence of the rare reciprocal translocation t(3;12)(q26.2;p13). <i>Leukemia Research</i> , 2007, 31, 1599-1600.	0.8	1

#	ARTICLE	IF	CITATIONS
289	Skin and stomach graft versus host disease after syngeneic BMT in CML: A case report. <i>Leukemia Research</i> , 2007, 31, 1603-1604.	0.8	1
290	RAF-1 over-expression does condition survival of patients affected by aggressive mantle cell lymphoma. <i>Leukemia Research</i> , 2007, 31, 1595-1597.	0.8	3
291	Poor prognosis chronic myeloid leukemia with a complex variant Philadelphia translocation, t(9;10;22)(q34;q24;q11). <i>Leukemia Research</i> , 2007, 31, 1765-1766.	0.8	9
292	NQO1*2 polymorphism and response to treatment in patients with multiple myeloma. <i>Leukemia Research</i> , 2007, 31, 1029-1030.	0.8	10
293	Association of PIM gene translocation and TEL/AML1 rearrangement. <i>Leukemia Research</i> , 2007, 31, 1761-1762.	0.8	1
294	Central nervous system graft-versus-host disease: consider progressive multifocal leukoencephalopathy among the differential diagnoses. <i>Bone Marrow Transplantation</i> , 2007, 40, 1095-1096.	2.4	2
295	Association of folate transporter SLC19A1 polymorphisms with the outcome of multiple myeloma after chemotherapy and tandem autologous transplantation. <i>Leukemia</i> , 2007, 21, 176-178.	7.2	10
296	Molecular detection of GNNK ⁺ and GNNK ⁻ c-kit isoforms: a new tool for risk stratification in adult acute myeloid leukaemia. <i>Leukemia</i> , 2007, 21, 2056-2058.	7.2	5
297	MDR1 polymorphism influences the outcome of multiple myeloma patients. <i>British Journal of Haematology</i> , 2007, 137, 454-456.	2.5	45
298	Unexpected cardiotoxicity in haematological bortezomib treated patients. <i>British Journal of Haematology</i> , 2007, 138, 396-397.	2.5	181
299	Atypical APL including multiple translocations and abnormal response to micronuclei induction test. <i>European Journal of Clinical Investigation</i> , 2007, 37, 155-156.	3.4	0
300	Concomitant appearance of trisomy 8 and isochromosome 17q in a Philadelphia-positive clone in a patient with chronic myeloid leukemia in chronic phase: an alarm for changing therapeutic strategy. <i>Cancer Genetics and Cytogenetics</i> , 2007, 177, 166-167.	1.0	1
301	Folate levels in cancer: a vitamin for a new challenge. <i>Annals of Hematology</i> , 2007, 86, 389-389.	1.8	0
302	Stable low IgG levels in relapsed non-Hodgkin's lymphomas. <i>Annals of Hematology</i> , 2007, 86, 851-853.	1.8	1
303	Hairy Cell Leukemia. <i>Current Treatment Options in Oncology</i> , 2007, 8, 129-134.	3.0	5
304	Role of Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) in Inducing and Maintaining Complete Molecular Response in B Non Hodgkin's Lymphoma Patients in Clinical Complete Remission after Chemotherapy Regimen. <i>Blood</i> , 2007, 110, 4498-4498.	1.4	1
305	Pharmacogenetic Study on Multiple Myeloma Patients Treated with DAV Regimen and Autologous Stem Cell Transplantation. <i>Blood</i> , 2007, 110, 3468-3468.	1.4	0
306	Cell clonality in hypereosinophilic syndrome: what pathogenetic role?. <i>Clinical and Experimental Rheumatology</i> , 2007, 25, 17-22.	0.8	16

#	ARTICLE	IF	CITATIONS
307	Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia. <i>Lancet Oncology</i> , The, 2006, 7, 350-352.	10.7	28
308	Simultaneous appearance of acute myeloid leukemia in a patient with bilateral primary uveal melanoma. <i>Melanoma Research</i> , 2006, 16, 467-468.	1.2	4
309	Granulocytic sarcoma and subsequent acute leukemia recurrence with different biologic characteristics 5 years after allogeneic bone marrow transplantation for acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2006, 37, 897-898.	2.4	8
310	Chronic myeloid leukaemia and hairy cell leukaemia coexisting in a single patient: Difficulties at diagnosis and rational of the therapeutic strategy. <i>Leukemia Research</i> , 2006, 30, 349-353.	0.8	6
311	Different \hat{T}^3/\hat{T}^4 T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation. <i>Leukemia Research</i> , 2006, 30, 529-535.	0.8	14
312	Actin polymerization in neutrophils from donors of peripheral blood stem cells: Divergent effects of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factor. <i>American Journal of Hematology</i> , 2006, 81, 318-323.	4.1	16
313	Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. <i>Leukemia Research</i> , 2005, 29, 961-966.	0.8	56
314	Imatinib therapy in Hypereosinophilic Syndrome: A case of molecular remission. <i>Leukemia Research</i> , 2005, 29, 1097-1098.	0.8	7
315	Glycosylated or non-glycosylated G-CSF differently influence human granulocyte functions through RhoA. <i>Leukemia Research</i> , 2005, 29, 1285-1292.	0.8	14
316	Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment. <i>Cancer Genetics and Cytogenetics</i> , 2005, 162, 57-62.	1.0	38
317	Chimerism does not influence graft-versus-myeloma and graft-versus-host disease in reduced intensity setting. <i>Transplant Immunology</i> , 2005, 15, 173-177.	1.2	7
318	Comparison of Bone Marrow Biopsy, Flow Cytometry and PCR Assays To Detect Bone Marrow Involvement in B-Cell Non-Hodgkin Lymphomas.. <i>Blood</i> , 2005, 106, 4670-4670.	1.4	0
319	High efficacy of Rituximab in indolent HCV-related lymphoproliferative disorders associated with systemic autoimmune diseases. <i>Clinical and Experimental Rheumatology</i> , 2005, 23, 877-80.	0.8	10
320	Role of Low-Dose 2-CdA in Refractory or Resistant Lymphoplasmocytic Lymphoma. <i>Journal of Chemotherapy</i> , 2004, 16, 388-391.	1.5	5
321	Adjunctive chromosomal abnormalities in Philadelphia-negative cells of CML patients treated with Imatinib. <i>European Journal of Clinical Investigation</i> , 2004, 34, 243-244.	3.4	5
322	A myeloablative allograft after rejection of two consecutive nonmyeloablative transplants from two different HLA identical siblings. <i>Bone Marrow Transplantation</i> , 2004, 33, 659-660.	2.4	0
323	Contemporaneous appearance, 18 years after allogeneic bone marrow transplantation, of myelodysplastic syndrome in the patient and the donor. <i>Bone Marrow Transplantation</i> , 2004, 33, 859-861.	2.4	10
324	Rituximab as treatment for minimal residual disease in hairy cell leukaemia. <i>European Journal of Haematology</i> , 2004, 73, 412-417.	2.2	51

#	ARTICLE	IF	CITATIONS
325	Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis. <i>European Journal of Haematology</i> , 2004, 72, 45-51.	2.2	15
326	Carboxy-terminal fragment of osteogenic growth peptide regulates myeloid differentiation through RhoA. <i>Journal of Cellular Biochemistry</i> , 2004, 93, 1231-1241.	2.6	17
327	Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients. <i>Leukemia Research</i> , 2004, 28, 367-372.	0.8	46
328	Bone and bone marrow interactions: hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. <i>Leukemia Research</i> , 2004, 28, 1097-1105.	0.8	4
329	Quantitative Molecular Evaluation of Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia. <i>Journal of Immunotherapy</i> , 2004, 27, 389-393.	2.4	3
330	Low dose 2-CdA schedule activity in splenic marginal zone lymphomas. <i>Hematological Oncology</i> , 2003, 21, 163-168.	1.7	23
331	Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. <i>British Journal of Haematology</i> , 2003, 120, 405-412.	2.5	27
332	Carboxy-terminal fragment of osteogenic growth peptide in vitro increases bone marrow cell density in idiopathic myelofibrosis. <i>British Journal of Haematology</i> , 2003, 121, 76-85.	2.5	12
333	Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by Rituximab. <i>Bone Marrow Transplantation</i> , 2003, 32, 57-63.	2.4	88
334	Dose-dependent induction of apoptosis by R-apomorphine in CHO-K1 cell line in culture. <i>Neuropharmacology</i> , 2003, 45, 182-189.	4.1	9
335	The Clinical Relevance of the Expression of Several Multidrug-Resistant-Related Genes in Patients with Primary Acute Myeloid Leukemia. <i>Journal of Chemotherapy</i> , 2003, 15, 374-379.	1.5	16
336	FLT3 mutations do not influence MDR-1 gene expression in acute myeloid leukemia. <i>Anticancer Research</i> , 2003, 23, 3419-26.	1.1	5
337	The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2002, 29, 581-587.	2.4	8
338	Oral Cyclophosphamide Therapy for Patients with Residual or Relapsed Indolent-Type Lymphoma after Initial Treatment for Aggressive Lymphomas. A Sub-group of Patients with Apparent Transformed Indolent Lymphoma. <i>Leukemia and Lymphoma</i> , 2002, 43, 1803-1806.	1.3	1
339	Bone and bone marrow interactions: hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. <i>Leukemia Research</i> , 2002, 26, 839-848.	0.8	12
340	Bone and bone-marrow interactions: haematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. Mobilizing properties on white blood cells and peripheral blood stem cells in mice. <i>Leukemia Research</i> , 2002, 26, 19-27.	0.8	17
341	Interferon- γ activity in a case of severe autoimmune lymphoproliferative disease. <i>Annals of Hematology</i> , 2001, 80, 49-52.	1.8	4
342	Unusual morphology in a case of large granular cell leukemia. <i>Annals of Hematology</i> , 2001, 80, 755-757.	1.8	1

#	ARTICLE	IF	CITATIONS
343	Arsenic and all-trans retinoic acid as induction therapy before autograft in a case of relapsed resistant secondary acute promyelocytic leukemia. Bone Marrow Transplantation, 1999, 24, 345-348.	2.4	17
344	An advantageous method to evaluate IgH rearrangement and its role in minimal residual disease detection. Leukemia Research, 1999, 23, 921-929.	0.8	29
345	Multidrug resistance related genes and p53 expression in human non small cell lung cancer. Anticancer Research, 1998, 18, 2973-6.	1.1	19
346	The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma. , 0, .		1